Provide definitive evidence on the effectiveness, safety, and mechanisms of low titer group O whole blood (LTOWB) and tranexamic acid (TXA) as resuscitation strategies for the treatment of…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00047
- Awardee
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $21,110,221
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 21% obligated
-
- $37,609,453.78 Current, with exercised options
- $99,317,105.78 Potential, with all options
- Completion date 31% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Pittsburgh, PA 15260, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,302,522 | |
| Original award | $19,807,699 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a $99.317 million cost-no-fee definitive contract to University Of Pittsburgh - Of The Commonwealth System Of Higher Education for clinical trial research on low-titer group O whole blood and tranexamic acid as resuscitation strategies for pediatric traumatic hemorrhage, with ultimate completion September 29, 2033 and award date September 30, 2023.
The originating solicitation, a BARDA Broad Agency Announcement posted October 16, 2017, sought advanced research and development of medical countermeasures including therapeutics and diagnostics. Place of performance is Pittsburgh, PA. The contract conducts a multicenter randomized clinical trial (MATIC-2) examining LTOWB and TXA effectiveness in children with life-threatening bleeding, including FDA IND acquisition and single institutional review board approval. Pediatric trauma mortality from hemorrhagic shock remains substantially higher than adult rates despite similar pathophysiology; the trial addresses the gap between pediatric clinical needs and evidence derived primarily from adult data.
The University of Pittsburgh engages a geographically distributed team of academic medical centers and clinical research sites as subcontractors, including The Medical College of Wisconsin, University of Rochester, University of Texas Health Science Center at San Antonio, University of Texas Southwestern Medical Center, Johns Hopkins University, University of California San Diego, Arkansas Children's Research Institute, University of Alabama at Birmingham, Tulane University, Emory University, Vanderbilt University Medical Center, University of Washington, Washington University, University of Mississippi Medical Center, University of New Mexico Health Sciences Center, Wake Forest University Health Sciences, University of Utah, University of Colorado-Denver, Oregon Health & Science University, University of California Davis, and Baylor College of Medicine, with a multi-vendor clinical trial infrastructure spanning pediatric trauma networks nationwide.
Service Contract Inventory data shows $7.7 million invoiced across FY2024–FY2025 with 23.8 FTEs and a rising blended prime-plus-subcontractor rate of $153.17/hr (average). Subcontractors delivered approximately 9% of hours in FY2025 across 24 named partners, indicating University of Pittsburgh's role as coordinating prime with distributed clinical trial delivery.
Description
Provide definitive evidence on the effectiveness, safety, and mechanisms of low titer group O whole blood (LTOWB) and tranexamic acid (TXA) as resuscitation strategies for the treatment of life-threatening bleeding secondary to traumatic injury in CH
Subawards
Show 19 more
Latest 29 listed here. See the rest on GovTribe.
Quick answers
Who was awarded contract 75A50123C00047?
75A50123C00047 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2023.
How much is contract 75A50123C00047 worth?
The government has obligated $21,110,221 on 75A50123C00047. Its current value, with exercised options, is $37,609,454. Its potential value, with all options, is $99,317,106.
Was contract 75A50123C00047 competed?
The extent of competition for 75A50123C00047 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award